Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04278118
Other study ID # IRB00114529
Secondary ID NCI-2019-06446RA
Status Recruiting
Phase N/A
First received
Last updated
Start date February 18, 2020
Est. completion date April 30, 2025

Study information

Verified date June 2023
Source Emory University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells. A shorter duration of radiation treatment may avoid some of the delayed side effects of radiation while providing a more convenient treatment and reducing costs.


Description:

PRIMARY OBJECTIVE: I. To report 3 year local tumor control of moderately hypofractionated proton or photon therapy for benign intracranial tumors. SECONDARY OBJECTIVES: I. To demonstrate feasibility of moderate hypofractionation pencil beam scanning proton therapy for intracranial tumors. II. To report physician reported acute and late toxicity of moderate hypofractionation pencil beam scanning proton therapy for intracranial tumors according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. III. To report neurocognitive effects, health related quality of life, and patient reported toxicity for moderate hypofractionation pencil beam scanning proton therapy for intracranial tumors. OUTLINE: Patients are assigned to 1 of 2 cohorts. COHORT I: Patients with benign and radiographically diagnosed intracranial tumors undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 17 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity. COHORT II: Patients with pathologically confirmed World Health Organization (WHO) grade 2-3 meningiomas undergo hypofractionated proton or photon radiation therapy daily, Monday-Friday over 20 fractions for 3.5-4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date April 30, 2025
Est. primary completion date April 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pathologically or radiographically diagnosed benign intracranial or nerve sheath tumor, including meningiomas, pituitary adenomas, schwannomas. World Health Organization (WHO) grade 2-3 meningiomas are also allowed - Recommended to receive proton or photon fractionated radiation therapy - Signed informed consent Exclusion Criteria: - Pregnant females are excluded. Female of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy. FCBP must agree to use adequate contraception (at least one highly effective method and one additional method of birth control at the same time or complete abstinence) prior to study entry, for the duration of study. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. - A female of childbearing potential (FCBP) is a sexually mature woman who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 12 consecutive months (if age >= 55 years); if the female subject is < 55 years and she has been naturally postmenopausal for >= 1 year her reproductive status has to be verified by additional laboratory (lab) tests (< 20 estradiol OR estradiol < 40 with follicle stimulating hormone [FSH] > 40 in women not on estrogen replacement therapy) - Prior radiation therapy that would overlap with current target volume - Inability to undergo magnetic resonance imaging (MRI)

Study Design


Intervention

Radiation:
Hypofractionated Radiation Therapy
Undergo hypofractionated proton or photon radiation therapy
Photon Beam Radiation Therapy
Undergo hypofractionated proton or photon radiation therapy
Proton Beam Radiation Therapy
Undergo hypofractionated proton or photon radiation therapy
Other:
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies

Locations

Country Name City State
United States Emory University Hospital/Winship Cancer Institute Atlanta Georgia

Sponsors (2)

Lead Sponsor Collaborator
Emory University National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary local tumor control Will assess local tumor control rate. Local tumor control is defined as freedom from progressive disease (PD). Will be calculated as the proportion of patients who did not experience PD within 3-year follow up with 95% binomial proportion confidence interval for the entire population and each cohort independently. The same calculation will be repeated for the entire study population and each cohort separately. Kaplan-Meier method will be used to estimate the local control rates for the entire population and each cohort independently. Up to 3 years since enrollment
Primary Incidence of adverse events Will be assessed and graded according to Common Terminology Criteria for Adverse Events version 5.0 up to 3 years
Secondary Neurocognitive effects Will be summarized by summary statistics. Up to 3 years
Secondary Health related quality of life Will be summarized by summary statistics. Up to 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05732896 - Comparison of Opioid Consumption During TCI Guided by NOL Index or Standard Care Undergoing Intracranial Tumor Surgery N/A
Completed NCT04044937 - Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms Phase 2
Not yet recruiting NCT03717766 - Application of New Technologies in the Resection of Intracranial Tumors
Completed NCT05145049 - The Relationship of Anesthesia Method With Serum Lactate Level in Craniotomies
Terminated NCT03089749 - Characterization of Human Autoantibody Titers After Central Nervous System Insult
Not yet recruiting NCT05891002 - Accuracy of Robotically Assisted Cranial Biopsies
Recruiting NCT06291662 - Evaluation of Performance Characteristics and Applicability in Oncology of Devices Customized Medical Devices Made by 3D Printing N/A
Completed NCT04302857 - Tractography Pilot Study Leipzig
Completed NCT04454268 - Intracranial Hydatid Cyst N/A
Completed NCT03076255 - Head and Neck Maskless Immobilization Device in Immobilizing Patients With Head and Neck Cancer or Intracranial Tumors Undergoing Radiation Therapy N/A
Recruiting NCT03714347 - The Effect of Cerebral Oxygenation on Postoperative Recovery in Intracranial Surgery N/A
Completed NCT03710278 - The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat)
Withdrawn NCT03091803 - QSM and Regional DCE MRI Permeability Using GOCART Technique
Completed NCT03539731 - [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers Phase 1
Recruiting NCT05904704 - Oxygen-Enhanced MRI for Generating Hypoxia Maps in Patients With Intracranial Tumors N/A